| Dr Frances Koblenzer, MD | |
|
410 Boot Rd, Downingtown, PA 19335-3405 | |
| (610) 873-1010 | |
| Not Available |
| Full Name | Dr Frances Koblenzer |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 410 Boot Rd, Downingtown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598876930 | NPI | - | NPPES |
| MD 046122L | Other | PENNSYLVANIA LICENSE | |
| 001498620 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 35-087618 (Ohio) | Primary |
| Entity Name | Human Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245403237 PECOS PAC ID: 2062495476 Enrollment ID: O20040608000771 |
News Archive
Researchers are being urged to differentiate between two types of bladder cancer when they carry out studies, after a detailed trends analysis revealed significant differences between the main subtypes of the disease.
In a study published in Nutrition Research, researchers looked at the association of out-of-hand nut (OOHN) consumption with nutrient intake, diet quality and the prevalence of risk factors for cardiovascular disease and metabolic syndrome in both children and adults.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
A Simon Fraser University chemist is the lead author on a new paper that advances scientific understanding of the structure and function of glycoproteins, in particular the number and positioning of sugars on them.
BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.
› Verified 6 days ago
| Entity Name | Klinger Counseling & Consulting Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417523358 PECOS PAC ID: 6507261591 Enrollment ID: O20210830002268 |
News Archive
Researchers are being urged to differentiate between two types of bladder cancer when they carry out studies, after a detailed trends analysis revealed significant differences between the main subtypes of the disease.
In a study published in Nutrition Research, researchers looked at the association of out-of-hand nut (OOHN) consumption with nutrient intake, diet quality and the prevalence of risk factors for cardiovascular disease and metabolic syndrome in both children and adults.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
A Simon Fraser University chemist is the lead author on a new paper that advances scientific understanding of the structure and function of glycoproteins, in particular the number and positioning of sugars on them.
BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frances Koblenzer, MD 175 Springdell Rd, Coatesville, PA 19320-5115 Ph: (610) 357-9267 | Dr Frances Koblenzer, MD 410 Boot Rd, Downingtown, PA 19335-3405 Ph: (610) 873-1010 |
News Archive
Researchers are being urged to differentiate between two types of bladder cancer when they carry out studies, after a detailed trends analysis revealed significant differences between the main subtypes of the disease.
In a study published in Nutrition Research, researchers looked at the association of out-of-hand nut (OOHN) consumption with nutrient intake, diet quality and the prevalence of risk factors for cardiovascular disease and metabolic syndrome in both children and adults.
Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care.
A Simon Fraser University chemist is the lead author on a new paper that advances scientific understanding of the structure and function of glycoproteins, in particular the number and positioning of sugars on them.
BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.
› Verified 6 days ago
Robert Seymour Newbrough, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 455 Boot Road, Downingtown, PA 19335 Phone: 484-237-5000 Fax: 610-444-3495 |